July 25, 2022
Article
Frequent recurrence of Clostridioides difficile infection drives up financial burdens of the disease and underscores the need to improve access to treatment, infection prevention, and new therapies.
June 20, 2022
Video
Eric Shaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.
June 08, 2022
SER-109, the investigational oral microbiome therapeutic from Seres, reduced C diff recurrence by 91.3% in at-risk populations.
June 03, 2022
Fecal microbiota transplant was a cost-effective treatment for recurrent C diff infection 90% of the time.
May 23, 2022
Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of recipients.
May 03, 2022
Today, the FDA approved vonoprazan dual and triple therapies, developed by Phathom Pharmaceuticals to treat adults with H. pylori infection.
April 13, 2022
In a small retrospective study, 7 of 11 patients experienced clinical improvement.
January 10, 2022
Rising sea temperatures cause Vibrio species, bacteria linked to gastroenteritis, to be identified for the first time in UK waters.
January 04, 2022
Underweight elderly pneumonia patients were more likely to contract C difficile infection.
December 08, 2021
For the first time, investigators proved that a higher presence of Clostridioides difficile bacteria and toxins cause a more severe infection.
Risk of Maternal Morbidity Differs by COVID-19 Variant
HIV Associated with Rapid Age Acceleration, New Study Finds
Frozen Meat Pizzas Recalled Due to Possible Metal Contaminants
Novavax Seeks FDA Authorization for its COVID-19 Vaccine as Booster
